Mechanisms of Adstiladrin Sensitivity and Resistance in Bladder Cancer

Abstract

Intravesical interferon gene therapy is being developed by our lab as an alternative treatment for patients with BCG-unresponsive bladdercancer. With the clinical samples (tissue and urine) from the phase 3 clinical trial, we proposed to perform deep genomic sequencing andmetabolomic analyses to identify novel predictive biomarkers that will be used to develop novel combination studies to overcomeresistance. At this study site (MD Anderson Cancer Center), we will also use preclinical models to complement our clinical studies by a)characterizing the effects of Ad-IFN on tumor microenvironment and b) define the role of fatty acid metabolism in Ad-IFN induced celldeath.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2022
Accession Number
AD1191190

Entities

People

  • Colin P. Dinney

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biological Factors
  • Biomedical Research
  • Bladder Cancer
  • Cancer
  • Cell Line
  • Cells
  • Clinical Trials
  • Fatty Acids
  • Gene Expression
  • Gene Therapy
  • Governments
  • Humanities
  • Interferon
  • Local Governments
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Professional Development
  • Proteins
  • Resistance
  • Therapy

Fields of Study

  • Medicine

Readers

  • Molecular and Cellular Biology
  • Oncology
  • Polymer Science and Engineering.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech